Induction Chemotherapy Before Chemoradiation Betters Survival in Locally Advanced Cervical Cancer
October 23rd 2023Data presented at the 2023 ESMO Congress and showed that induction chemotherapy followed by chemoradiation reduced the risk of progression or death by 35% vs chemoradiation alone in patients with cervical cancer.
Read More
Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma
October 22nd 2023The addition of nivolumab to frontline standard of care gemcitabine-cisplatin, followed by nivolumab maintenance therapy, led to statistically significant and clinically meaningful improvements in survival compared with gemcitabine-cisplatin alone in patients with unresectable or metastatic urothelial carcinoma.
Read More
Survival Benefit Shown With Niraparib Plus Abiraterone in BRCA+ mCRPC
October 22nd 2023Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Read More
Enfortumab Vedotin/Pembrolizumab Shows Encouraging Survival Data in mUC
October 22nd 2023Thomas Powles, MD, MBBS, MRCP, discusses findings from the phase 3 EV-302 clinical trial of enfortumab vedotin-ejfv with pembrolizumab vs chemotherapy for the treatment of patients with previously untreated locally advanced or metastatic urothelial cancer.
Read More
Selpercatinib Shows Superior Efficacy Vs Multikinase Inhibitors in Advanced RET+ MTC
October 21st 2023A trial comparing selpercatinib with cabozantinib or vandetanib led to greater benefit and favorable safety in the selpercatinib arm, supporting use of the selective RET inhibitor as first-line treatment for patients with advanced RET-mutant medullary thyroid cancer, according to interim data presented at the 2023 ESMO Congress.
Read More
EGFR Exon 20-Insertion NSCLC Population Sees PFS Benefit from Amivantamab/Chemotherapy
October 21st 2023Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.
Read More
Selpercatinib Improves Survival vs Chemotherapy in RET+ NSCLC
October 21st 2023Results phase 3 LIBRETTO-431 trial presented at the 2023 ESMO Congress showed selpercatinib monotherapy demonstrated better survival results than chemotherapy with or without pembrolizumab for patients with RET fusion–positive non–small cell lung cancer.
Read More
In ALK+ NSCLC Alectinib Reduces Disease Risks in Early-Stage Setting
October 21st 2023Results from the phase 3 ALINA trial showed the benefit of ALK inhibition for patients with ALK-positive, early-stage, non–small-cell lung cancer with use of adjuvant alectinib significantly improving disease-free survival.
Read More
Following Progression on ICIs Lifileucel Shows Anti-tumor Response in Advanced Mucosal Melanoma
October 21st 2023Results of from a subgroup of patients in the phase 2 C-144-01 study with advanced mucosal melanoma showed a clinically meaningful response to lifileucel after progression on immune checkpoint inhibitors.
Read More
Evidence of Activity with Etigilimab Plus Nivolumab Seen in Recurrent/Advanced Solid Tumors
October 21st 2023The emergence of preliminary efficacy evidence, and potential biomarker targets, with the combination of the novel anti-TGIT agent etigilimab and nivolumab was presented at the 2023 ESMO Congress.
Read More
Addition of Adjuvant Nivolumab Improves EFS in NSCLC
October 21st 2023In the first phase 3 perioperative study of patients with resectable non–small cell lung cancer given adjuvant nivolumab after surgery and a prior regimen of nivolumab and chemotherapy showed improved event-free survival results.
Read More
Durvalumab/Olaparib Maintenance Induces PFS Benefit in Advanced, Recurrent Endometrial Cancer
October 21st 2023Adding durvalumab to chemotherapy, followed by durvalumab and olaparib maintenance therapy improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer.
Read More
Adjuvant Cemiplimab Shows Survival Benefit For Responders in CSCC
October 21st 2023One-year follow-up of the phase 2 study assessing the use of neoadjuvant and adjuvant cemiplimab in patients with cutaneous squamous cell carcinoma shows a promising survival benefit that has led to a wider phase 3 study.
Read More
Atezolizumab Plus Chemo Improves PFS in Frontline, Advanced/Recurrent Endometrial Cancer
October 21st 2023The addition of atezolizumab to chemotherapy improved progression-free survival in frontline advanced or recurrent endometrial carcinoma, in particular, among patients with deficient mismatch repair status.
Read More
Modest Activity With Sacituzumab Govitecan in Pretreated HNSCC
October 21st 2023Modest but durable antitumor activity was observed with sacituzumab govitecan-hziy in the treatment of patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.
Read More
Pembrolizumab/Chemoradiotherapy Shows Clinically Meaningful PFS Improvement in Cervical Cancer
October 20th 2023Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.
Read More